Mittag Diana, Batori Vincent, Neudecker Philipp, Wiche Regina, Friis Esben P, Ballmer-Weber Barbara K, Vieths Stefan, Roggen Erwin L
Allergy Unit, Department of Dermatology, University Hospital Zurich, Switzerland.
Mol Immunol. 2006 Feb;43(3):268-78. doi: 10.1016/j.molimm.2005.02.008.
A clinically relevant allergic reaction requires recognition of at least two different epitopes on the surface of the allergen by IgE. These epitopes may be specific or cross-reactive. Moreover, patterns of IgE reactivity may be patient-specific. The aim of our study was to compare specific and cross-reactive IgE epitopes and epitope patterns between individual patients. We used Bet v 1-related food allergy as a model.
Five patients were investigated by cross-competitive ELISA for specific and cross-reacting IgE to Bet v 1, and its homologues Gly m 4 (soybean), Ara h 8 (peanut), and Pru av 1 (cherry). Allergen-specific as well as cross-reactive IgE epitopes were assessed by competitive immunoscreening of a phage-displayed random 7-mer peptide library using polyclonal purified IgE from individual sera. The resulting peptide mimics were mapped on the surface of the 3D-structure of the allergens using a computer-based algorithm.
Competitive immunoscreening and epitope mapping identified patient-specific IgE epitope patterns. However, one IgE-binding surface area that was recognized by all patients and two recognized by three patients were identified on all four proteins. These results are consistent with the determination of IgE cross-reactivity of the individual patients' sera against the four recombinant allergens by cross-competitive ELISA.
Selection of phage-displayed peptide mimics with serum IgE from allergic patients in combination with computer-based mapping of the peptide mimics onto the surface of the three-dimensional allergen structure is a promising novel tool to investigate IgE epitope specificity in individual patients. Such basic information on epitope structure may be used for prediction of cross-reactivity and potential allergenicity of novel foods.
临床上具有相关性的过敏反应需要IgE识别过敏原表面至少两种不同的表位。这些表位可能是特异性的或交叉反应性的。此外,IgE反应模式可能因患者而异。我们研究的目的是比较个体患者之间特异性和交叉反应性IgE表位及表位模式。我们以与Bet v 1相关的食物过敏作为模型。
通过交叉竞争ELISA研究了5名患者针对Bet v 1及其同源物Gly m 4(大豆)、Ara h 8(花生)和Pru av 1(樱桃)的特异性和交叉反应性IgE。使用来自个体血清的多克隆纯化IgE,通过对噬菌体展示的随机7肽文库进行竞争性免疫筛选,评估过敏原特异性以及交叉反应性IgE表位。使用基于计算机的算法将所得的肽模拟物定位到过敏原三维结构的表面上。
竞争性免疫筛选和表位定位确定了患者特异性的IgE表位模式。然而,在所有四种蛋白质上均鉴定出一个所有患者都识别的IgE结合表面积和两个三名患者识别的IgE结合表面积。这些结果与通过交叉竞争ELISA测定个体患者血清针对四种重组过敏原的IgE交叉反应性一致。
将过敏患者血清中的噬菌体展示肽模拟物与基于计算机的肽模拟物在三维过敏原结构表面的定位相结合,是研究个体患者IgE表位特异性的一种有前景的新工具。这种关于表位结构的基础信息可用于预测新型食物的交叉反应性和潜在致敏性。